NZ567150A - Compositions and methods for treatment of autoimmune disease - Google Patents

Compositions and methods for treatment of autoimmune disease

Info

Publication number
NZ567150A
NZ567150A NZ567150A NZ56715006A NZ567150A NZ 567150 A NZ567150 A NZ 567150A NZ 567150 A NZ567150 A NZ 567150A NZ 56715006 A NZ56715006 A NZ 56715006A NZ 567150 A NZ567150 A NZ 567150A
Authority
NZ
New Zealand
Prior art keywords
self
vector
polypeptide
dna
protein
Prior art date
Application number
NZ567150A
Other languages
English (en)
Inventor
Nanette Solvason
Michael Leviten
Hideki Garren
Original Assignee
Bayhill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc filed Critical Bayhill Therapeutics Inc
Publication of NZ567150A publication Critical patent/NZ567150A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NZ567150A 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease NZ567150A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72420305P 2005-10-05 2005-10-05
PCT/US2006/038776 WO2007044394A2 (en) 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
NZ567150A true NZ567150A (en) 2011-12-22

Family

ID=37943343

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ567150A NZ567150A (en) 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease

Country Status (9)

Country Link
US (1) US20100160415A1 (https=)
EP (1) EP1931390B1 (https=)
JP (1) JP2009511014A (https=)
CN (1) CN101365494A (https=)
AU (1) AU2006302477A1 (https=)
CA (1) CA2624615A1 (https=)
IL (1) IL190520A0 (https=)
NZ (1) NZ567150A (https=)
WO (1) WO2007044394A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540085C (en) 2003-09-29 2010-11-16 Bruce Michael Koivisto High alcohol content gel-like and foaming compositions
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
CN103417388A (zh) 2005-03-07 2013-12-04 戴博全球保健有限公司 含有有机硅表面活性剂的高醇含量发泡组合物
WO2010151420A1 (en) * 2009-06-05 2010-12-29 Bayhill Therapeutics, Inc. Compositions and methods for treatment of insulin-dependent diabetes mellitus
WO2011091138A1 (en) * 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
US9222107B2 (en) 2011-05-25 2015-12-29 National University Corporation Okayama University REIC-expressing adenovirus vector
KR101466875B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
KR101466874B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 자가면역 질환의 예방과 치료를 위한 il-6 수용체에 대한 항체를 발현하는 미니서클
CA2929273C (en) 2013-11-22 2022-05-31 Amarna Holding B.V. Method for restoring immune tolerance in vivo
EP3090263A4 (en) * 2013-12-31 2017-08-23 Yeda Research and Development Co., Ltd. Methods for assaying immunological competence
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
US12605432B2 (en) 2014-06-04 2026-04-21 Diamyd Medical Ab Combinations for antigen based therapy
US20170196949A1 (en) * 2014-06-04 2017-07-13 Diamyd Medical Ab Novel combinations for antigen based therapy
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3472193A4 (en) * 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
PL3534936T3 (pl) 2016-11-01 2021-01-25 Novo Nordisk A/S Szczepionka tolerogennego dna
SG11202012710WA (en) * 2018-06-25 2021-01-28 Akouos Inc Methods of treating clrn1-associated hearing loss and/or vision loss
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU4973199A (en) * 1998-07-09 2000-02-01 Merck & Co., Inc. Polynucleotide vaccine formulations
CA2361421A1 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2003011118A2 (en) * 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
CN1652770A (zh) * 2002-03-29 2005-08-10 利兰·斯坦福青年大学托管委员会 使用抑制素和其它免疫调节剂治疗自身免疫病
WO2005035771A2 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Nucleic acid constructs

Also Published As

Publication number Publication date
IL190520A0 (en) 2008-11-03
WO2007044394A3 (en) 2007-07-12
EP1931390B1 (en) 2012-07-25
EP1931390A4 (en) 2009-04-15
CA2624615A1 (en) 2007-04-19
EP1931390A2 (en) 2008-06-18
AU2006302477A1 (en) 2007-04-19
JP2009511014A (ja) 2009-03-19
US20100160415A1 (en) 2010-06-24
WO2007044394A2 (en) 2007-04-19
CN101365494A (zh) 2009-02-11

Similar Documents

Publication Publication Date Title
US7544669B2 (en) Polynucleotide therapy
US20100160415A1 (en) Compositions and methods for treatment of autoimmune disease
US20100048679A1 (en) Polynucleotide therapy
US20030229044A1 (en) Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
EP1569696B1 (en) Methods and immune modulatory nucleic acid compositions for preventing and treating disease
AU2008201186B2 (en) Polynucleotide therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 OCT 2016 BY CPA GLOBAL

Effective date: 20131003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2017 BY CPA GLOBAL

Effective date: 20160819

ASS Change of ownership

Owner name: TOLERION, INC., US

Effective date: 20170216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2018 BY CPA GLOBAL

Effective date: 20180308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2019 BY CPA GLOBAL

Effective date: 20180823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20200918

LAPS Patent lapsed